<DOC>
	<DOC>NCT00356356</DOC>
	<brief_summary>The purpose of this study was to evaluate extended safety and efficacy of etanercept in adults with Ankylosing Spondylitis.</brief_summary>
	<brief_title>16.0040 Ankylosing Spondylitis Study</brief_title>
	<detailed_description>This multicenter, open-label extension study will evaluate the safety and clinical benefit of etanercept in the treatment of Ankylosing Spondylitis in subjects previously enrolled in Protocol 16.0037.</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects completing 24 weeks of study drug in protocol 16.0037 qualify to enroll into this study Other patients to meet the following criteria: Negative pregnancy test Subjects agree to use appropriate contraception throughout study Should be able to selfinject study drug or have someone who can do so Capable of understanding protocol and willing to provide written informed consent Any change in NSAID or prednisone dose within 2 weeks of baseline Any change in hydroxychloroquine, sulfasalazine, or MTX dose within 4 weeks of baseline Use of DMARDs other than those mentioned above, within 4 weeks of enrollment Previous receipt of aniTNF agents, other than etanercept Receipt of any other investigational drug within 30 days of baseline Grade 3 or 4 adverse event attributed to etanercept which recurred when etanercept was resumed Abnormality in chemistry or hematology profiles or significant concurrent medical events.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>